We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bayer and Loxo Oncology have announced plans to work together to develop and commercialize two cancer therapies in a deal that potentially brings Loxo up to $1.55 billion over the coming few years.